Jack W Hsu
Overview
Explore the profile of Jack W Hsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1072
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guru Murthy G, Logan B, Bo-Subait S, Beitinjaneh A, Devine S, Farhadfar N, et al.
Am J Hematol
. 2023 Jan;
98(4):608-619.
PMID: 36606713
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). While many factors influence the outcomes of allo-HCT, the independent...
2.
Farhadfar N, Ahn K, Bo-Subait S, Logan B, Stefanski H, Hsu J, et al.
Transplant Cell Ther
. 2022 Jun;
28(9):603.e1-603.e7.
PMID: 35688325
There is a lack of evidence about how health-related quality of life (HRQoL), including psychosocial factors, might affect donation-related experiences and clinical markers in the context of hematopoietic stem cell...
3.
Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, et al.
Front Immunol
. 2021 Sep;
12:700045.
PMID: 34539628
We report a first in-depth comparison of immune reconstitution in patients with HIV-related lymphoma following autologous hematopoietic cell transplant (AHCT) recipients (n=37, lymphoma, BEAM conditioning), HIV(-) AHCT recipients (n=30, myeloma,...
4.
Desai P, Brown J, Gill S, Solh M, Akard L, Hsu J, et al.
J Clin Oncol
. 2021 Jun;
39(29):3261-3272.
PMID: 34156898
Purpose: Standard cytotoxic induction chemotherapy for acute myeloid leukemia (AML) results in prolonged neutropenia and risk of infection. Romyelocel-L is a universal, allogeneic myeloid progenitor cell product being studied to...
5.
Hsu J, Farhadfar N, Murthy H, Logan B, Bo-Subait S, Frey N, et al.
Transplant Cell Ther
. 2021 Apr;
27(6):507-516.
PMID: 33865804
The COVID-19 pandemic has resulted in the increased use of cryopreserved grafts for allogeneic hematopoietic cell transplantation (HCT). However, information about the effect of cryopreservation on outcomes for patients receiving...
6.
Panch S, Logan B, Sees J, Bo-Subait S, Savani B, Shah N, et al.
Transplant Cell Ther
. 2021 Apr;
27(6):503.e1-503.e8.
PMID: 33823169
Approximately 7% of unrelated hematopoietic stem cell donors are asked to donate stem cells a subsequent time to the same or a different recipient. Recent studies have shown that donation-related...
7.
Hu B, Lin X, Lee H, Huang X, Slack Tidwell R, Ahn K, et al.
Leuk Lymphoma
. 2020 Jul;
61(12):2811-2820.
PMID: 32662346
While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residual life expectancy (RLE) for patients initially diagnosed...
8.
Farhadfar N, Kelly D, Mead L, Nair S, Colee J, Irizarry Gatell V, et al.
Biol Blood Marrow Transplant
. 2020 Feb;
26(6):1154-1159.
PMID: 32105830
Hematopoietic stem cell transplantation (HCT) survivors are burdened by a high prevalence and early onset of chronic diseases. Healthy dietary patterns have been associated with lower risks of chronic health...
9.
Farhadfar N, Hsu J, Logan B, Sees J, Chitphakdithai P, Sugrue M, et al.
Blood Adv
. 2020 Feb;
4(4):706-716.
PMID: 32092138
There are limited data on the effect of donor body mass index (BMI) on peripheral blood stem cell (PBSC) mobilization response to granulocyte colony-stimulating factor (G-CSF), especially in unrelated donors....
10.
Hsu J, Shaw B, Kim S, Logan B, Sees J, Confer D, et al.
Biol Blood Marrow Transplant
. 2020 Feb;
26(6):1210-1217.
PMID: 32088366
Peripheral blood stem cells (PBSCs) have been increasingly used for allogeneic hematopoietic cell transplantation instead of bone marrow stem cells. Current National Marrow Donor Program policy recommends 5 days of...